Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 9/2020

01-09-2020 | Obesity | Original Contributions

The Positive Effects of a Calorie-Restricting High-Protein Diet Combined with Intragastric Botulinum Toxin Type A Application Among Morbidly Obese Patients: A Prospective, Observational Analysis of Eighty-Seven Grade 2 Obese Patients

Authors: Murat Ferhat Ferhatoglu, Abdulcabbar Kartal, Ali Ilker Filiz, Abut Kebudi

Published in: Obesity Surgery | Issue 9/2020

Login to get access

Abstract

Purpose

Many studies evaluating the effect of intragastric botulinum toxin type A injection (IG-BTxA) for the treatment of obesity have been published. However, none of these studies combined this procedure with a calorie-restricting high-protein diet. Herein, we aimed to evaluate the effects of IG-BTxA application combined with a calorie-restricting high-protein diet.

Materials and Methods

This prospective cohort study is conducted with eighty-seven grade 2 obese patients treated between January 2019 and August 2019. Group 1: IG-BTxA + refused to consult the dietitian; group 2: IG-BTxA + get calorie-restricting high-protein diet; group 3: only get a calorie-restricting high-protein diet. Loss of weight, treatment adaptation (visual analog scale score), the status and changes of comorbid conditions, and changes in eating behaviors (Self-Regulation of Eating Behaviour Questionnaire score) were assessed.

Results

Loss of weight, treatment adaptation, and positive behavioral change in eating preferences were significantly higher in group 2 (p = 0.01; p = 0.001; p < 0.01, respectively). Additionally, the decrease in medication requirement for diabetes and hypertension was higher in group 2 (p < 0.05).

Conclusion

IG-BTxA application before calorie-restricting high-protein diet facilitates adaptation to the new diet style and helps to lose weight faster in grade 2 obese patients. Also, more positive results were achieved in terms of controlling comorbid diseases.
Literature
1.
Bassett MT, Perl S. Obesity: the public health challenge of our time. Am J Public Health. 2004;94:1477.CrossRef
2.
Hurt RT, Kulisek C, Buchanan LA, et al. The obesity epidemic: challenges, health initiatives, and implications for gastroenterologists. Gastroenterol Hepatol (N Y). 2010;6:780–92.
3.
Mittermair R, Keller C, Geibel J. Intragastric injection of botulinum toxin A for the treatment of obesity. Obes Surg. 2007;17:732–6.CrossRef
4.
Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA. 1999;282:1530–8.CrossRef
5.
Coskun H, Duran Y, Dilege E, et al. Effect on gastric emptying and weight reduction of botulinum toxin-A injection into the gastric antral layer: an experimental study in the obese rat model. Obes Surg. 2005;15:1137–43.CrossRef
6.
Picot J, Jones J, Colquitt JL, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1–190.CrossRef
7.
Meunier FA, Schiavo G, Molgó J. Botulinumneurotoxinss: from paralysis to the recovery of functional neuromuscular transmission. J Physiol. 2002;96:105–13.
8.
Junior AC, Savassi-Rocha PR, Vaz Coelho LG, et al. Botulinum a toxin injected into the gastric wall for the treatment of class III obesity: a pilot study. Obes Surg. 2006;16:335–43.CrossRef
9.
Osio M, Mailland E, Muscia F, et al. Botulinum neurotoxin-a does not spread to distant muscles after intragastric injection: a double-blind single-fiber electromyography study. Muscle Nerve. 2010;42:165–9.CrossRef
10.
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. National Institutes of Health. Obes Res. 1998;2:51–209.
11.
Aasprang A, Andersen JR, Våge V, et al. Ten-year changes in health-related quality of life after biliopancreatic diversion with duodenal switch. Surg Obes Relat Dis. 2016;12:1594–600.CrossRef
12.
Kliemann N, Beeken RJ, Wardle J, et al. Development and validation of the self-regulation of eating behaviour questionnaire for adults. Int J Behav Nutr Phys Act. 2016;13:87.CrossRef
13.
Liu SY, Wong SK, Lam CC, et al. Long-term results on weight loss and diabetes remission after laparoscopic sleeve gastrectomy for a morbidly obese Chinese population. Obes Surg. 2015;25:1901–8.CrossRef
14.
Flores L, Vidal J, Canivell S, et al. Hypertension remission 1 year after bariatric surgery: predictive factors. Surg Obes Relat Dis. 2014;10:661–5.CrossRef
15.
Sada A, Asaad M, Reidt WS, et al. Are in-person post-operative clinic visits necessary to detect complications among bariatric surgery patients? Obes Surg 2019 [Ahead of print- online print]
16.
Bigalke H, Habermann E. Blockade by tetanus and botulinum A toxin of postganglionic cholinergic nerve endings in the myenteric plexus. Naunyn Schmiedeberg’s Arch Pharmacol. 1980;312:255–63.CrossRef
17.
Jones OM, Brading AF, Mortensen NJ. Mechanism of action of botulinum toxin on the internal anal sphincter. Br J Surg. 2004;9:224–8.CrossRef
18.
James AN, Ryan JP, Parkman HP. Inhibitory effects of botulinum toxin on pyloric and antral smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2003;285:291–7.CrossRef
19.
Topazian M, Camilleri M, De La Mora-Levy J, et al. Endoscopic ultrasound-guided gastric botulinum toxin injections in obese subjects: a pilot study. Obes Surg. 2008;18:401–7.CrossRef
20.
Albani G, Petroni M, Mauro A, et al. Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study. J Gastroenterol. 2005;40:833–5.CrossRef
21.
Gui D, Mingrone G, Valenza V, et al. Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese patients: a pilot study. Aliment Pharmacol Ther. 2006;23:675–80.CrossRef
22.
Garcia-Compean D, Mendoza-Fuerte E, Martinez J, et al. Endoscopic injection of botulinum toxin in the gastric antrum for the treatment of obesity. Results of a pilot study. Gastroenterol Clin Biol. 2005;29:789–91.CrossRef
23.
Foschi D, Corsi F, Lazzaroni M, et al. Treatment of morbid obesity by intraparieto gastric administration of botulinum toxin: a randomized, double-blind, controlled study. Int J Obes. 2007;31:707–12.CrossRef
24.
Li L, Liu QS, Liu WH, et al. Treatment of obesity by endoscopic gastric intramural injection of botulinum toxin A: a randomized clinical trial. Hepato-Gastroenterology. 2012;59:2003–7.PubMed
25.
Peeters TL. Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders. Curr Opin Pharmacol. 2006;6:553–8.CrossRef
26.
Rollnik J, Meier P, Manns M, et al. Antral injections of botulinum A toxin for the treatment of obesity. Ann Intern Med. 2003;138:359–60.CrossRef
27.
Helmiö M, Victorzon M, Ovaska J, et al. Comparison of short-term outcome of laparoscopic sleeve gastrectomy and gastric bypass in the treatment of morbid obesity: a prospective randomized controlled multicenter SLEEVEPASS study with 6-month follow-up. Scand J Surg. 2014;103:175–81.CrossRef
28.
Salminen P, Helmiö M, Ovaska J, et al. Effect of laparoscopic sleeve gastrectomy vs. laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA. 2018;319:241–54.CrossRef
29.
Peterli R, Wölnerhanssen BK, Peters T, et al. Effect of laparoscopic sleeve gastrectomy vs. laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA. 2018;319:255–65.CrossRef
30.
Bhandari M, Reddy M, Kosta S, et al. Laparoscopic sleeve gastrectomy versus laparoscopic gastric bypass: a retrospective cohort study. Int J Surg. 2019;67:47–53.CrossRef
31.
Garg H, Priyadarshini P, Aggarwai S, et al. Comparative study of outcomes following laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy in morbidly obese patients: a cas- control study. World J Gastrointest Endosc. 2017;9:162–70.CrossRef
32.
Graham B, Green A, James M, et al. Measuring patient satisfaction in orthopaedic surgery. JBJS. 2015;97:80–4.CrossRef
33.
De Vet H, Terwee C, Mokkink L, et al. Development of a measure- ment instrument. Measurement in medicine: a practical guide. Practical guides to biostatistics and epidemiology. Cambridge: Cambridge University Press; 2011. p. 30–64.
34.
Rosenzveig A, Kuspinar A, Daskalopoulou SS, et al. Toward patient-centered care: a systematic review of how to ask questions that matter to patients. Medicine. 2014;93:120.CrossRef
35.
Arman GA, Himpens J, Dhaenens J, et al. Long-term (11+years) outcomes in weight, patient satisfaction, comorbidities, and gastro- esophageal reflux treatment after laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2016;12:1778–86.CrossRef
Metadata
Title
The Positive Effects of a Calorie-Restricting High-Protein Diet Combined with Intragastric Botulinum Toxin Type A Application Among Morbidly Obese Patients: A Prospective, Observational Analysis of Eighty-Seven Grade 2 Obese Patients
Authors
Murat Ferhat Ferhatoglu
Abdulcabbar Kartal
Ali Ilker Filiz
Abut Kebudi
Publication date
01-09-2020
Publisher
Springer US
Published in
Obesity Surgery / Issue 9/2020
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-020-04597-y

Other articles of this Issue 9/2020

Obesity Surgery 9/2020 Go to the issue

Original Contributions

Comparative Safety and Effectiveness of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy in Obese Elder Patients: a Systematic Review and Meta-analysis

Multimedia Article

Fistulojejunostomy for Chronic Fistula After Sleeve Gastrectomy

Original Contributions

Leakage Risk Stratification After Laparoscopic Sleeve Gastrectomy (LSG): Is There a Role for Routine Postoperative CT Scan?

Original Contributions

The Effect of Laparoscopic Gastric Bypass Surgery on Insulin Resistance and Glycosylated Hemoglobin A1c: a 2-Year Follow-up Study

Original Contributions

Comparing the Efficacy and Safety of Roux-en-Y Gastric Bypass with One-Anastomosis Gastric Bypass with a Biliopancreatic Limb of 200 or 160 cm: 1-Year Results of the Tehran Obesity Treatment Study (TOTS)

Letter to the Editor

COVID-19 Digestive Symptoms Mimicking Internal Hernia Presentation After Roux-en-Y-Gastric Bypass; Comment on “Internal Hernia in the Times of COVID-19: to Laparoscope or Not to Laparoscope?”